Krishna Rao1,2,3, Kavitha Santhosh1,2, Jill A Mogle1,2, Peter D R Higgins2,4, Vincent B Young1,2,5. 1. a Divisions of Infectious Diseases , University of Michigan School of Medicine , Ann Arbor , MI , USA ; 2. b Department of Internal Medicine , University of Michigan School of Medicine , Ann Arbor , MI , USA ; 3. c Division of Infectious Diseases , Veterans Affairs Ann Arbor Healthcare System , Ann Arbor , MI , USA ; 4. d Department of Gastroenterology , University of Michigan School of Medicine , Ann Arbor , MI , USA ; 5. e Department of Microbiology and Immunology , University of Michigan School of Medicine , Ann Arbor , MI , USA.
Abstract
BACKGROUND: Clostridium difficile infection (CDI) causes a mild to moderate colitis in most patients, but some, especially older adults, develop severe, adverse outcomes. Biomarkers predicting outcomes are needed to optimize treatments. This study tested whether fecal calprotectin associated with a composite primary outcome of complicated CDI (intensive care unit admission, colectomy, or death due to CDI within 30 days of diagnosis) and/or 8-week recurrence. METHODS: Stool was collected in Cary-Blair media at the time of diagnosis from inpatients of age >60 years that tested positive for C. difficile (enzyme immunoassay [EIA] for toxin A/B or polymerase chain reaction for the tcdB gene). Fecal calprotectin was measured and normalized to solid stool weight. Analysis was performed using logistic regression. Variables were selected for the final model using likelihood ratio tests. RESULTS: Fifty patients were included with a mean age 72.8 (± 7.5), and 13 (26%) developed the primary outcome. Clinical variables such as age, gender, and comorbid disease did not associate with complicated CDI/recurrence, nor did traditional biomarkers such as serum albumin or white blood cell count. A high normalized fecal calprotectin (>2000 μg/g) associated with the primary outcome in the final model after adjustment for gender and detectable fecal toxin(s) by EIA (OR 24.9, 95% CI 2.4-257.9, p = 0.007) with a specificity of 91.9%. CONCLUSION: This study provides evidence that fecal calprotectin level associates with complications from CDI in older adults. Further studies are required to validate these findings in larger cohorts and incorporate them into clinical prediction algorithms.
BACKGROUND:Clostridium difficileinfection (CDI) causes a mild to moderate colitis in most patients, but some, especially older adults, develop severe, adverse outcomes. Biomarkers predicting outcomes are needed to optimize treatments. This study tested whether fecal calprotectin associated with a composite primary outcome of complicated CDI (intensive care unit admission, colectomy, or death due to CDI within 30 days of diagnosis) and/or 8-week recurrence. METHODS: Stool was collected in Cary-Blair media at the time of diagnosis from inpatients of age >60 years that tested positive for C. difficile (enzyme immunoassay [EIA] for toxin A/B or polymerase chain reaction for the tcdB gene). Fecal calprotectin was measured and normalized to solid stool weight. Analysis was performed using logistic regression. Variables were selected for the final model using likelihood ratio tests. RESULTS: Fifty patients were included with a mean age 72.8 (± 7.5), and 13 (26%) developed the primary outcome. Clinical variables such as age, gender, and comorbid disease did not associate with complicated CDI/recurrence, nor did traditional biomarkers such as serum albumin or white blood cell count. A high normalized fecal calprotectin (>2000 μg/g) associated with the primary outcome in the final model after adjustment for gender and detectable fecal toxin(s) by EIA (OR 24.9, 95% CI 2.4-257.9, p = 0.007) with a specificity of 91.9%. CONCLUSION: This study provides evidence that fecal calprotectin level associates with complications from CDI in older adults. Further studies are required to validate these findings in larger cohorts and incorporate them into clinical prediction algorithms.
Authors: Christina M Surawicz; Lawrence J Brandt; David G Binion; Ashwin N Ananthakrishnan; Scott R Curry; Peter H Gilligan; Lynne V McFarland; Mark Mellow; Brian S Zuckerbraun Journal: Am J Gastroenterol Date: 2013-02-26 Impact factor: 10.864
Authors: Jonathan N V Martinson; Susan Broadaway; Egan Lohman; Christina Johnson; M Jahangir Alam; Mohammed Khaleduzzaman; Kevin W Garey; Jessica Schlackman; Vincent B Young; Kavitha Santhosh; Krishna Rao; Robert H Lyons; Seth T Walk Journal: J Clin Microbiol Date: 2015-01-28 Impact factor: 5.948
Authors: Alain M Schoepfer; Christoph Beglinger; Alex Straumann; Ekaterina Safroneeva; Yvonne Romero; David Armstrong; Carsten Schmidt; Michael Trummler; Valérie Pittet; Stephan R Vavricka Journal: Inflamm Bowel Dis Date: 2013-02 Impact factor: 5.325
Authors: Jason A Trubiano; Bradley Gardiner; Jason C Kwong; Peter Ward; Adam G Testro; Patrick G P Charles Journal: Eur J Gastroenterol Hepatol Date: 2013-02 Impact factor: 2.566
Authors: Yogesh M Shastri; Dominik Bergis; Nada Povse; Volker Schäfer; Sarika Shastri; Martin Weindel; Hans Ackermann; Jürgen Stein Journal: Am J Med Date: 2008-12 Impact factor: 4.965
Authors: Amoe Baktash; Elisabeth M Terveer; Romy D Zwittink; Bastian V H Hornung; Jeroen Corver; Ed J Kuijper; Wiep Klaas Smits Journal: Front Microbiol Date: 2018-06-12 Impact factor: 5.640
Authors: Joseph P Zackular; Reece J Knippel; Christopher A Lopez; William N Beavers; C Noel Maxwell; Walter J Chazin; Eric P Skaar Journal: mSphere Date: 2020-03-11 Impact factor: 4.389
Authors: Joseph P Zackular; Jessica L Moore; Ashley T Jordan; Lillian J Juttukonda; Michael J Noto; Maribeth R Nicholson; Jonathan D Crews; Matthew W Semler; Yaofang Zhang; Lorraine B Ware; M Kay Washington; Walter J Chazin; Richard M Caprioli; Eric P Skaar Journal: Nat Med Date: 2016-09-26 Impact factor: 53.440